Mitogen- and stress-activated kinase 1 (MSK1) was recently identified as an important marker and regulator of metastatic dormancy in ER+ BC patients, indicating that stratifying patients according to MSK1 expression could improve prognosis [175]. The gene discussed is RPS6KA5; the disease is breast cancer.